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Abstract: Biofilms are the cause of major bacteriological infections in patients. The complex
architecture of Escherichia coli (E. coli) biofilm attached to the surface of catheters has been studied
and found to depend on the biomaterial’s surface properties. The SEM micrographs and water
contact angle analysis have revealed that the nature of the surface affects the growth and extent of
E. coli biofilm formation. In vitro studies have revealed that the Gram-negative E. coli adherence
to implanted biomaterials takes place in accordance with hydrophobicity, i.e., latex > silicone >
polyurethane > stainless steel. Permanent removal of E. coli biofilm requires 50 to 200 times more
gentamicin sulfate (G-S) than the minimum inhibitory concentration (MIC) to remove 90% of E. coli
biofilm (MBIC90). Here, in vitro eradication of biofilm-associated infection on biomaterials has been
done by Eudragit RL100 encapsulated gentamicin sulfate (E-G-S) nanoparticle of range 140 nm. It
is 10–20 times more effective against E. coli biofilm-associated infections eradication than normal
unentrapped G-S. Thus, Eudragit RL100 mediated drug delivery system provides a promising way to
reduce the cost of treatment with a higher drug therapeutic index.
Keywords: E. coli; biofilm; nanoparticle-mediated drug delivery; antibiotics; catheters; biomaterials
1. Introduction
The biomedical devices used in the management of vital health functions are the backbone of
modern medicine. Catheters made of different biomaterials like polyurethane, silicone rubber, polyvinyl
chloride, polypropylene, polyethylene, Teflon etc. are the most common externally implanted medical
devices (EIDs) [1]. With the advancement in medical technology, a significant increase in implant-related
cases of biofilm-associated infections over EIDs has emerged as a major global health challenge [2].
Proper screening for new catheter/implant materials with desirable biocompatibility and antibacterial
property for prevention of biofilm formation is still a matter of research [3]. Biofilm-associated
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infections have become the most dangerous type of virulent factor for the majority of infectious
pathogenic microorganisms. There is a high incidence of biofilm-associated infections on artificial
implanted devices such as catheters, orthopedic implants, stents, contact lenses, and other electronic
health support devices [4]. Chronic catheter-associated biofilm infections are frequently caused by
Gram-positive as well as Gram-negative bacteria [5–7]. The prevention of catheter-related infections
by premature removal of catheters has led to an increase in treatment cost [8].
Considerable efforts have been made to develop new antimicrobial agents for preventing
biofilm-associated infections [9]. The development of new antibiotics and widespread application of
existing antibiotics has led to the growth of tolerant microorganisms either by mutation of genes or by
change in the mode of their proliferation [10].
Microbial communities can adhere to different surfaces using extracellular polymeric substance’s
(EPS) microenvironment, composed mainly of polysaccharides, proteinaceous molecules, lipids, mucus,
and some extracellular DNA, and get embedded deep inside the EPS. Such a micro-environment
improves the bacterial resistance against various factors like biocides, host defense and unfavorable
environmental conditions [11,12]. The microbes in the deepest layer of biofilm are resistant to antibiotics
as the EPS layers limit their exposure to antibiotics. The bacteria residing in biofilm colonies are
metabolically dormant, which makes them resistant to conventional biocides sometimes 1000-fold
more than the planktonic forms of the same strain [6].
The antibiotic resistance may involve either production of some inhibitor enzymes or modification
of the cell permeability to enhance multidrug resistance. The genes for antibiotic resistance have been
reported for lateral transfer along bacterial biofilms. Failure of antibiotic treatment of biofilm-related
infections makes the task of treatment extremely challenging, resulting in delayed, expensive treatment
or sometimes surgical removal of the implant [13].
Nearly 80% of human bacterial infections are biofilm-associated. E. coli, Pseudomonas aeruginosa,
Staphylococcus epidermidis and Staphylococcus aureus are among the most prominent causative agents.
The catheter’s surface always remains in touch with biological fluids, thus providing an excellent
platform for bacterial attachment and proliferation. The duration of catheterization is a major
determinant for biofilm formation on all EIDs. Nearly 20% of the cases of healthcare acquired bacterial
infections in acute care facilities and more than 50% in long term care facilities are catheter-associated
urinary tract infections. [14]. Due to the lack of well-defined treatment protocol for biofilm-associated
infections, biofilm-associated iatrogenic infections contribute significantly to patient morbidity and
healthcare costs. Few possible strategies, such as targeting the regulators and eradicating biofilms,
have already been investigated [15]. Bacterial cells produce and release some signaling molecules for
communication to regulate a wide variety of characteristic functions including biofilm formation by
the phenomenon of quorum sensing (QS) [16]. QS inhibitors have been used either for interrupting or
degrading or modifying QS signals [17,18]. EPS matrix-degrading enzymes have been shown to act by
the degradation of polysaccharides, DNA, or proteinaceous components in biofilm matrix [19].
Antimicrobial peptides modify the attachment, influence QS systems, and promote twitching
motility [20]. Surfactants like CTAB, Tween 20, Triton X-100, rhamnolipids, etc. have also been
found to be effective in lowering the surface tension to detach adherent bacterial cells leading to
biofilm dispersion [21,22]. Free fatty acids tend to inhibit initial attachment by altering cell membrane
function [23]. Amino acids like D-amino acid, L-tryptophan and glutamate trigger biofilm disassembly
inducing biofilm dispersion [24]. Indole and its derivatives affect transcription in pathogenic E. coli [25].
Metal chelators act by increasing the sensitivity of cells to biocidal agents [26], nitric oxide donors
induce biofilm dispersion [27], sometimes a combination of two or more techniques also used for
biofilm inhibition [28].
Material surfaces play a vital role in microbial attachment and propagation, still they are quite often
neglected, and only a few guidelines and microbiological assessment protocols are available [29]. To
overcome the problem of surface contamination, new strategies are being developed and used for surface
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modification and functionalization [30]. Use of surfaces with incorporated antimicrobial properties or
modified with active biological nanometals are some of the recently proposed strategies [31,32].
In this work, a comparative study of the available catheter materials has been performed for
microbial attachment, and their surface properties have been compared to come out with parameters
to select the best material resistant to biofilm formation. A new drug-entrapped nanoparticle-based
approach to prevent catheter-associated infections has also been tested. The antibiotic gentamicin
sulfate (G-S) has been encapsulated in Eudragit RL100, which swells partially at physiological pH, thus
acting as decent material for the prolonged drug release [33]. The E. coli bacteria are studied for their
initial adhesion and ability to form mature biofilm colonies on different catheter biomaterials, namely
latex rubber (rubber catheter), silicone rubber (Foley catheter) and polyurethane (endotracheal tube
and enteral feeding catheter). Stainless steel (316L) plates, which are commonly used in orthopedic
implants, have also been tested for biofilm formation study.
2. Results
2.1. Biofilm Formation and Quantification
Variation of biofilm formation with time is shown in Figure 1. It is seen that the maximum biofilm
formation occurred over rubber (latex) and Foley urethral catheter after 48 h of incubation while over
enteral feeding and endotracheal catheter after 24 h. Crystal violet assay leads to purple staining of
the bacterial cells that are attached to the surface whereas abiotic surfaces are not stained. The rubber
(latex) catheter has been found to be a more susceptible surface for biofilm formation, and the bacteria
show a greater tendency to form the biofilm. The different patterns of biofilm formation over the EID
surfaces indicate that the bacterial biofilm formation depends on the surface properties like texture,
grooves, surface charge, and other surface properties of the EIDs.
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Figure 1. Graphical pattern of E. coli biofilm formation over different materials.
2.2. Physical Characteristic of Indwelling Devices
The SEM of EIDs surfaces showed differences in polymer surface structures (Figure 2). The external
surface of rubber (latex) is more irregular, with grooves (Figure 2a), thus it provided a better site for
microbial attachment and c used rich biofilm formation over it (Figure 2b). Dense rod-shaped E. coli
bacterial colonies can e visualized on the rubber catheter surface. The Foley catheter made of silicone
also has surface irregularities (Figure 2c), but the depressions are not as prominent as in case of rubber
catheter. The micr bial attachment over the surface is clearly visible (Figure 2d). The enteral feeding
and endotracheal catheter (polyurethane) surface showe the fewest irregularities (Figure 2e,f) and
had few sites available for microbial attachments.
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steel (316L SS) plate used for the biomedical application also showed hydrophilic nature. Considering 
the nature of the surfaces and WCA, the order of hydrophilic nature is stainless steel > polyurethane 
> silicone rubber > latex rubber and the same is the order for E. coli biofilm formation over the 
specimens suggesting the possible interdependence between the nature of the material and biofilm 
formation apart from the other physical factors. 
Figure 2. SEM images of catheter inner surfaces before and after E. coli biofilm formation; (a) rubber
catheter; (b) biofilm over rubber catheter; (c) Foley catheter; (d) biofilm over Foley catheter;
(e) endotracheal catheter; (f) biofilm over endotracheal catheter.
2.3. Contact Angle Measurement
The hydrophilic and hydrophobic properties of the surfaces of the EIDs were analyzed with the
help of water drop contact angles. The surface with a water contact angle (WCA) <90◦ has been
considered hydrophilic while the surface with WCA >90◦ considered hydrophobic. The latex rubber
catheter surface is hydrophobic while the Foley catheter (silicone rubber) and the endotracheal tube
and enteral feeding catheter made of polyurethane surfaces are hydrophilic (Figure 3). The stainless
steel (316L SS) plate used for the biomedical application also showed hydrophilic nature. Considering
the nature of the surfaces and WCA, the order of hydrophilic nature is stainless steel > polyurethane >
silicone rubber > latex rubber and the same is the order for E. coli biofilm formation over the specimens
suggesting the possible interdependence between the nature of the material and biofilm formation
apart from the other physical factors.
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Figure 3. Contact angle of sessile water drop over different catheter surfaces.
2.4. Physical Characteristic of Nanoparticles
The SEM image of nanoparticle-encapsulating drugs showed that G-S nanoparticles size was
around 100–250 nm (Figure 4a). The nanoparticles were uniformly distributed. The particle size was
analyzed through dynamic light scattering (DLS) technique and was found in the range of 100–350 nm
(Figure 4b).
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2.5. Drug Entrapment Efficiency
Initially, the study started with G-S concentration of 142.8571 µg/mL, out of which only
100.2256 µg/mL got en rapped in Eudragit RL100 nanoparticles and 42.6315 µg/mL remained
unentrapped resulting i drug en rapment efficiency of 70.15%. The drug concentration calcul tions
were based on standard equa ion Y = 0.065X + 0.0129 at 260 nm.
In vit o dr g release from the nanosuspension in phosphate buffer (pH 7.4) was investigated
by the membrane diffusion tec nique. The sample was taken at regular interval of 2 h for 24 h.
The in vitro drug release profile was obtained from the dialysis xperiment. Initially a quick release is
seen, p obably due to diffusion, ut later on, the rele se slows down and becomes nearly con tant after
16 h. More than 70% of the en r pped drug gets r leased uri g this period (Figure 5).
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2.6. Minimum Inhibitory Concentration (MIC) Determination of G-S
The MIC value of G-S for E. coli was tested over nutrient agar plates, and the lawns of different
overnight grown test culture of E. coli ith a variabl concentration of G-S after incubation at 37 ◦C for
24 h are shown i Figure 6. On examination of the plate colonies, he growth of E. coli was observed up
t the concentratio of 0.18 µg/mL, but the col ny count decreased corresponding t ncrease of G-S
concentrati , and no gr wth was observed at 0.20 and 0.22 µg/mL concent ations. It can be seen that
at a G-S concentration above 0.20 µg/mL, the E. coli bacteria were unable to g ow, thus o firming
t the MIC value of G-S for E. coli bacteria is 0.20 µg/mL. Agar plate meth d provide qualitative
confirmatory test MIC of G-S.
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Figure 6. Minimum inhibitory concentration ( IC) observation of G-S for E. coli by visual detection of
colony forming nits (CFU).
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2.7. Minimum Biofilm Inhibitory Concentration (MBIC)
Biofilms are structured communities that are unable to show any explanatory drug resistance
by any single mechanism, and complete reduction or inhibition is difficult to achieve [20]. MBIC
is the lowest concentration of drug that can reduce the microbial biofilm by 50% (MBIC50) or 90%
(MBIC90). Based on percentage reduction in OD600 of spectrophotometric data MBIC50 for G-S in the
case of the rubber, Foley, and enteral feeding catheters were found to be 20 µg/mL (100 times that
of MIC), 10 µg/mL (50 times that of MIC), and 15 µg/mL (75 times that of MIC), respectively, while
MBIC90 for G-S in the case of the rubber, Foley, and enteral feeding catheters was found to be 30 µg/mL
(150 times that of MIC), 20 µg/mL (100 times that of MIC), and 25 µg/mL (125 times that of MIC),
respectively (Figure 7). It is seen that the MBIC value for EIDs was much higher as compared to
MIC value under similar conditions for the planktonic E. coli. The results demonstrate that in case of
sessile microbial biofilm, the drug added was not fully available to the microbes, and a major portion
of drug/antimicrobial agent was generally reacted and inactivated by chemicals or enzymes of EPS
matrix [11]. Polymeric matrix forms a physical barrier and prevents drug penetration, thus protecting
sessile microorganisms from being killed [28]. The adaptation acquired by bacterial cells in the biofilm
makes it difficult for the antibiotic to act over the biofilm bacterial colonies.
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2.8. Determination of MBIC of Eudragit RL100 Nanoparticle-Encapsulated G-S
The MBIC50 and MBIC90 values were calculated for E-G-S, which was used against biofilm in
this study. The values for MBIC50 for the nanoparticle-mediated drug delivery for latex, silicone,
and polyurethan catheters were found to be 2.5, 2.0, and 1.5 µg/mL, respectively. These concentratio s
are ve y low when compar d to those f normal unentrapped antibiotics (Figure 7). Similarly, the value
for MBIC90 for t e nano ticle-mediated drug deliv ry over latex, silicone, and polyurethane wer
found to be 4.0, 3.5, and 3.5 µg/mL, respectively (Figure 8). These concentrations are very much lower
than those for unentrapped antibiotics. Nanoparticle-encapsulating G-S MBIC50 a d MBIC90 were
about 8 and 25 times low r h n r spec ive MBIC for unentrapped G-S for latex (rubber catheter), 5 and
6 times l wer for silicone (Foley catheter) and 15 and 7 times lower for polyurethane (enteral feeding
and ndotracheal catheter).
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Figure 8. Comparision of minimum biofilm inhibitory concentration (MBIC): MBIC50 and MBIC90 of
G-S and E-G-S.
3. Discussion
The formation of biofilm is not uniform among the EIDs. Factors such as hydrophobicity,
the surface charge of microorganisms, and aterial from which c theter is m de, size, s ape, wa er
cont t angle, and topographical features of the surface also play a rol in microbial adherence to the
catheter surface [34]. The maximum endency for biofilm f rm tion in the cur ent stu y occurs ver
the la x r bber catheter followed by silicone rub er Foley catheter. In both cases, he duration for
maximum biofilm formation is 48 h. Th s may be due to their surface roughness, cracks, and fissure,
which is visible n SEM images (Figure 2). The depressions and irregularities allow the E. coli bacteria to
grow their colony up to a greater extent as they provide a site for microbial adhesion, and the complex
interplay between biofilm matrix and the catheter surface delays the detachment ph se of biofilm. On
the positive side, it may b said that although these surfaces are mor prone to biofilm formation, they
delay the bacterial migration preventing its further spread for a longer duration, and the ill effect may
c nfine to a local area. In contrast w th other catheters, enteral f eding and end tracheal catheters
(polyurethane) showed compar tively smoother surfaces few cr cks and grooves. Only a few
colony forming units (CFU) are seen in SEM images (Figure 2f), and the maximum biofilm occurs after
24 h. It is in accordance ith ur assumptions that smooth urfaces do not provide an easy b cterial
att ch ent, and if the bacteria get attached, it det ch s easily to pread t other sites. Stainless steel
316L is ery smooth, nd it h rdly provides any bacterial attachment sites. This i why negligible
biofilm formation occurred.
The water co tact angle analysis reveals that increase in hydrophilicity of EID surfaces has a
direct relation with he biofi m formation, i.e., moderate hydrop obic bioma erial surfaces provide a
bett r site for microbial pr liferation nd the hydr philic biomaterial surfaces are less prone to biofilm
formation. This finding is in accordance with Yue et al. [35], in that a moderate hydrophobicity with
water contact ngle around 90◦ s suitable for bacterial adhesion. Recent y superhydrophobic surfaces
are reported for reduced bacterial adhesion due to the maintenance of entrapp d ir betwee the liquid
and solid surface by reducing interface contact area and adhesion forces. This reduction i adhesion
forces results in asy detachment of bacterial cells. However, f the entrapped air are intru ed by the
bact rial media, then the roughness and increased effective attachment are r sult in adherence of more
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bacterial cells leading to prominent bacterial colonies [35,36]. The negatively charged bacterial surface
also plays a role for the bacterial attachment; the more positive the charge of the surface, the greater
the tendency of the microbe for surface attachment [34].
The size of E-G-S as measured by DLS technique (Figure 4b) [37] shows that the average
hydrodynamic particle diameter is 133.9 ± 40.9 nm in number distribution. The cumulative %
distribution of E-G-S from the DLS study reveals that a cumulative 20% of the particles are below the
size of 99.9 nm, 40% are below 109.6 nm, 60% are below 123.6 nm, 80% are below 148.3 nm, 95% are
below 202.6 nm.
The G-S entrapment efficiency of Eudragit RL-100 is 70.15%, which is very good because there
is extended-release time up to 16 h, and about 70% of the G-S gets released by that time. Thus, if
we see the larger picture, nearly 50% of the initial amount of drug is going to be utilised for the
biofilm eradication and prevention. If we compare and analyze the values, MBIC50 and MBIC90 of
unentrapped G-S and E-G-S (Figures 7 and 8), the latter is 5–10 times more efficient in removing the
biofilm. A smaller dose of E-G-S will be able to prevent and eradicate biofilm effectively.
Thus, the E-G-S is efficient in preventing and eradicating the biofilm over EIDs and is also safe as
it reduces the biological payload of antibiotics. It also helps to reduce the tolerant bacterial infection
within the subject’s body. Complete removal of formed biofilm is difficult to achieve, but the Eudragit
RL-100 nanoparticle-mediated drug delivery can efficiently act against the E. coli biofilms. Lower doses
of the drug are needed as the nanoparticles can easily penetrate the EPS to act directly on the target site
without exceeding the systemic toxicity value of the drug and preventing possible side effects [38].
The polymeric biomaterial surfaces are differentially susceptible to microbial colonization based on
their surface properties, and E-G-S nanoparticles offer a better perspective for catheter-associated
biofilm removal.
4. Materials and Methods
4.1. Materials and Reagents
Eudragit RL-100 was purchased from Evonik Rohm GmbH Darmstadt, and gentamicin sulfate
(G-S) and mannitol were purchased from Sigma-Aldrich, Saint Louis, MO, USA. Polyvinyl alcohol
(PVA), methylene dichloride (MDC), nutrient agar, phosphate-buffered saline (PBS), nutrient broth,
lysogeny broth (LB), crystal violet (CV), dimethyl sulfoxide, ethanol, disodium hydrogen phosphate,
potassium dihydrogen phosphate were purchased from Himedia Laboratories Pvt. Ltd., Mumbai,
India. The standard strain of E. coli ATCC 25922 was procured from Institute of Medical Sciences,
Banaras Hindu University, Varanasi, India, was used as the reference in this study. Externally implanted
medical devices (EIDs)/catheters (enteral feeding catheter (Ramsons Scientific & Surgical Industries
Pvt. Ltd., Agra, India), rubber catheter, Foley catheter (Ramsons Scientific & Surgical Industries Pvt.
Ltd., Agra, India) and stainless steel plates-(316L) (Zealmax Innovations Pvt. Ltd., Ahmedabad, India))
were obtained from local medical shops. All solvents and chemicals used were of analytical grade.
The borosilicate glass-wares used in experiments were acid-washed and rinsed with double-distilled
(DD) water followed by heat sterilization before use.
4.2. Biofilm Formation and Quantification
Biofilms were formed on the EIDs using the microtiter dish biofilm formation assay [39]. E. coli
strain was cultured in LB at 37 ◦C for 24 h, and the cell density was set at 1.5 × 108 cell/mL using
hemocytometer. One mL of 1.5× 108 CFU/mL of E. coli suspension was added to a 2 mL capped
eppendorf tube having (0.5 × 0.5) cm2 EIDs and incubated at 37 ◦C for 90–120 min (adhesion phase).
After incubation, EIDs were washed with PBS buffer, and then a fresh broth was added to the catheters,
and subsequently incubated at 37 ◦C for 24, 48, and 72 h for biofilm formation. Timely quantification
of biofilm was done by crystal violet assay [40]. The 0.5% (w/v) CV solution in DD water was applied
to the catheter pieces, and subsequently incubated for 30 min at room temperature. After 30 min of
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incubation, the blocks were rinsed thrice with PBS to remove any unbound dye. Later the CV was
washed out from the bacterial biofilms over the catheter surfaces with 96% ethanol, and the resultant
solution was spectrophotometrically analyzed for the absorption of the resulting violet solution at
600 nm using 96% ethanol as the blank [41].
4.3. Determination of Minimum Inhibitory Concentration (MIC) of G-S
The MIC of G-S was determined by the broth dilution method [42]. One mL of 1.5 × 108 CFU/mL
of E. coli in LB was taken in 2 mL eppendorf tubes. Different concentrations of G-S (0.10, 0.12, 0.14,
0.16, 0.18, 0.20, 0.22, 0.24 µg/mL) were then added to the eppendorfs. The tube containing LB and test
organism (without G-S) served as the positive control, while the tube containing only LB served as the
negative control. The capped tubes were then incubated with constant shaking at 37 ◦C for 24 h. After
incubation, the broth was streaked onto a sterile nutrient agar plate and again incubated at 37 ◦C for
24 h and the nutrient agar plate was examined for the absence of visual colonies for the minimum
G-S concentration. The sample in the eppendorf tubes was tested spectrophotometrically for visible
turbidity at 600 nm to verify the authenticity of the MIC test.
4.4. Determination of Minimum Biofilm Inhibitory Concentration (MBIC) of G-S
To determine the MBIC value of G-S different concentrations, 2, 5, 10, 15, 20, 25, 30 µg/mL of G-S
were used. The EID pieces of (0.5 × 0.5) cm2 containing 24 h grown biofilm were washed thrice and
incubated at 37 ◦C for 24 h along with positive control samples (without antibiotics). After incubation,
the EID pieces were analyzed for biofilm quantification by the crystal violet assay method described
earlier. The spectrophotometric absorbance at 600 nm for biofilm was compared with a positive
control to find out the MBIC values. Each MBIC experiment was conducted simultaneously with MIC
determination to reduce the error.
4.5. Preparation of Eudragit RL100 Nanoparticle-Encapsulating G-S
Nanoparticle-encapsulated G-S was prepared by the solvent displacement or nanoprecipitation
technique [33]. The PVA solution of known concentration (5% w/v in 100 mL distilled water) was
prepared and stirred at room temperature for 10 min to obtain a homogeneous solution. One hundred
mg of G-S was mixed in this solution. In a fresh Erlenmeyer flask, 5 g of Eudragit RL-100 was dissolved
in 100 mL of methylene dichloride (MDC) and sonicated for 5 s. The G-S solution was added to the
sonicated Eudragit RL-100 solution and further sonicated for 25 s to form a water in organic emulsion
(w/o). A fresh 250 mL of PVA solution (1% w/v) was then added in water in an oil emulsion to form
multiple emulsion (w/o/w). The resultant emulsion was homogenized at 15,000–20,000 rpm thrice to
form the Eudragit RL-100 nanoparticle encapsulated drug. Two hundred and fifty mL of PVA (0.3%
w/v) was prepared in DD water and mixed with multiple emulsion and placed on the magnetic stirrer
for 6 h at 25 ◦C at 200 rpm to evaporate the MDC and organic solvents. To get the nanoparticle in
powder form, deep-frozen samples were placed in a lyophilizer at −40 ◦C until the dried powdered
sample was obtained.
4.6. Drug Entrapment Efficiency
A 20 mL solution of the prepared nanosuspension was centrifuged at 18,000× g for 2.5 h at
10 ◦C, using Remi C-24 cooling centrifuge. The proportion of unentrapped drug was estimated by
taking the absorbance of the appropriately diluted supernatant solution at 260 nm using UV-Visible
Spectrophotometer (Systronics, Model 2202, Ahmedabad, India) against blank/control nanosuspension.
By subtracting the amount of G-S in supernatant from the initial amount of the G-S taken, entrapment
efficiency of nanoparticle was calculated using the formulas
Entrapment efficiency =
Amount of drug entrapped in nanoparticle
Initial amount of drug used
× 100 (1)
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Amount of drug entrapped = Initial amount of drug used – Drug present in the supernatant.
4.7. In Vitro Drug Release Kinetic Study
The in vitro drug release kinetics of the formed nanoparticle were studied by the static Franz
diffusion cell [43]. A dialysis membrane made of cellulose acetate of 25 mm diameter was placed at
the terminal portion of the donor compartment. A 10 mL portion of the nanosuspension with the
drug was placed into the donor compartment to act as a source. The receptor compartment was filled
with 90 mL of 0.2 M phosphate buffer solution of pH 7.4 maintained at 37 ◦C under mild agitation
using a magnetic stirrer. At predefined specific time intervals, aliquots of 1 mL were withdrawn and
immediately maintained with the same volume of fresh phosphate buffer solution. The amount of
drug released was estimated by taking the absorbance at 260 nm using a UV spectrophotometer.
4.8. Scanning Electron Microscopy (SEM)
The scanning electron microscopic (SEM) analysis was performed for determining the size of the
formed nanoparticles, the sample’s surface morphology of EIDs, and bacterial biofilm. All the EID
samples [(0.5 × 0.5) cm2] were pasted onto the sample holder, and E-G-S nanoparticles were allowed to
dry at ambient temperature before the measurement using scanning electron microscopy (FEI, Quanta
200F, Tokyo, Japan) at an acceleration voltage of 10 kV. Lyophilized E-G-S samples were also analyzed
for their size using Dynamic Light Scattering method (Particulate Systems, Nanoplus particle size
analyzer, Norcross Georgia, GA, USA) [37].
4.9. Contact Angle
The hydrophilicity and hydrophobicity of the EID surfaces were evaluated by the surface contact
angle measurement between the sessile water drop and EID surface. The contact angle measurement
for water was performed by using contact-angle-measuring drop-shape analyzer (DSA25S, KRUSS,
Hamburg, Germany). A drop of water (20 µL) was dropped over the piece of catheter material using
an automatic microsyringe, and then static images for each surface were taken [44]. In each case,
the angle was measured thrice, and the average value was taken as the contact angle value of that
material surface.
4.10. Antimicrobial Assessment
E. coli cells were grown at 37 ◦C for 24 h in LB media. Cell number was determined by using
a hemocytometer and agar plate counting method and adjusted to 1.5 × 108 CFU/mL. Different
concentrations of G-S were used to analyze the antimicrobial property.
4.11. Statistical Analysis
All data sets are measured and represented as mean standard deviation (SD), and experiments
have been performed at least in triplicate.
5. Conclusions
Material characteristics and surface properties are directly related to microbial adhesion,
colonization and detachment. Irregularities on the polymeric surface promote biofilm formation
because of the increased effective surface area for microbial attachment. The rough surfaces and
depressions in the uneven surfaces provide shelter and site for microbial colonization. In vitro studies
have confirmed that both adherence of biofilm and decrease in hydrophilicity increase in the order:
Stainless steel 316L < polyurethane < silicone < latex for Gram-negative E. coli, thus justifying the
differential susceptibility of polymer surfaces for the microbial colonization. The E-G-S nanopowder has
better protective property against the biofilm, so its coating or its powdered form is very effective against
prevention of biofilm-related infections. The study also confirms that the hydrophobic surfaces in the
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moderate range are more prone to bacterial cell attachment and biofilm formation, and the tendency to
form biofilm over the biomaterial decreases with increase in hydrophilicity. The polyurethane polymer
is found to be most suitable for the EIDs as compared to silicone and latex rubber.
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